These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28616304)

  • 1. Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial.
    Messas N; Tanguay JF; Lordkipanidzé M
    J Thorac Dis; 2017 May; 9(5):E440-E443. PubMed ID: 28616304
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of individually tailored antiplatelet therapy in patients with acute coronary syndrome after coronary stenting: a single center, randomized, feasibility study.
    Zhu HC; Li Y; Guan SY; Li J; Wang XZ; Jing QM; Wang ZL; Han YL
    J Geriatr Cardiol; 2015 Jan; 12(1):23-9. PubMed ID: 25678901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting.
    Costa F; Van Klaveren D; Feres F; James S; Räber L; Pilgrim T; Hong MK; Kim HS; Colombo A; Steg PG; Bhatt DL; Stone GW; Windecker S; Steyerberg EW; Valgimigli M;
    J Am Coll Cardiol; 2019 Feb; 73(7):741-754. PubMed ID: 30784667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
    Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
    Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z; Kala P
    Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
    Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Mielot C; Bali L; Lambert M; Alessi MC; Bonnet JL
    Thromb Haemost; 2007 Feb; 97(2):282-7. PubMed ID: 17264958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antiplatelet therapy in acute coronary syndromes: state of the art and new perspectives].
    Riva L; Di Pasquale G; Casella G; Calabrese D; Zagnoni S; Pallotti MG
    G Ital Cardiol (Rome); 2010 Dec; 11(12 Suppl 3):27S-33S. PubMed ID: 21491737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The incidence, clinical characteristics and risk factors of upper gastrointestinal bleeding in patients taking dual antiplatelet therapy after percutaneous coronary intervention in south China].
    Zhang ZF; Sha WH; Tan GY; Wang QY
    Zhonghua Nei Ke Za Zhi; 2016 Jun; 55(6):445-50. PubMed ID: 27256606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Not Available].
    Kuzmina NM; Maximov NI
    Kardiologiia; 2019 Jan; 59(1):36-38. PubMed ID: 30710987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors and Management of Antiplatelet-Related Bleeding Complications for Acute Coronary Syndrome in Chinese Elderly Patients.
    Wan J; Wang P; Zhou P; Liu S; Wang D; Kan J; Hou J; Zuo L; Ma S; Yang Y
    Cell Physiol Biochem; 2018; 50(3):1164-1177. PubMed ID: 30355936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review.
    Li-Sha G; Peng C; Yue-Chun L
    BMC Cardiovasc Disord; 2015 Sep; 15():101. PubMed ID: 26385102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELOAD-ACS] trial).
    Patti G; Pasceri V; Mangiacapra F; Colonna G; Vizzi V; Ricottini E; Montinaro A; D'Ambrosio A; Wijns W; Barbato E; Di Sciascio G;
    Am J Cardiol; 2013 Jul; 112(2):162-8. PubMed ID: 23601577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial.
    Sambola A; Montoro JB; Del Blanco BG; Llavero N; Barrabés JA; Alfonso F; Bueno H; Cequier A; Serra A; Zueco J; Sabaté M; Rodríguez-Leor O; García-Dorado D
    Am Heart J; 2013 Oct; 166(4):669-75. PubMed ID: 24093846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype-guided personalization of antiplatelet treatment: A meta-analysis of patients with ACS or undergoing PCI.
    Liu J; Qin L; Xi S; Tong W; Yuan M; Peng L; Liu J; Wang X; Zhang Y; Yin T
    Thromb Res; 2019 Jul; 179():87-94. PubMed ID: 31100633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Status of Antiplatelet Therapy in Acute Coronary Syndrome.
    Dash D
    Cardiovasc Hematol Agents Med Chem; 2015; 13(1):40-9. PubMed ID: 26245659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome.
    Dobesh PP; Phillips KW; Haines ST
    Am J Health Syst Pharm; 2008 Aug; 65(15 Suppl 7):S22-8. PubMed ID: 18653821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention: balancing efficacy and bleeding risk.
    Spinler SA
    Am J Health Syst Pharm; 2010 Aug; 67(15 Suppl 7):S7-17. PubMed ID: 20651327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
    Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
    Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.